Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Liraglutide (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Novo Nordisk Investigational Site
  Soeborg, Denmark
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Saxenda® (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Novo Nordisk Investigational Site
  Soeborg, Denmark
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Multiparametric, multinuclear MR (DMI/ 13C-MRS/ GlycoCEST/GlycoNOE) (diagnostic_test)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Inselspital, Bern University Hospital and University Hospital of Bern
  Bern, Switzerland
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Dapagliflozin 10mg (drug) — also listed as: forxiga
• Saxagliptin 5mg (drug) — also listed as: Onglyza
• Saxagliptin 5mg + Dapagliflozin 10 mg (drug) — also listed as: No other intervention name specified

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Department of Endocrinology and Metabolism, University of Pisa
  Pisa, Italy
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• REMD-477 (biological) — also listed as: Volagidemab

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Duke University Medical Center
  Durham, North Carolina, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Semaglutide Pen Injector [Ozempic] (drug)
• Very-low Calorie Diet (dietary_supplement)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• University of Nottingham, Royal Derby Hospital Centre
  Derby, United Kingdom
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• glucagon (other)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Aarhus University Hospital
  Aarhus, Danmark, Denmark
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Liraglutide (drug)
• Sitagliptin (drug)
• hypocaloric diet (other)
• Placebos (drug)
• Exendin (9-39) (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Vanderbilt University Medical Center
  Nashville, Tennessee, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• intensive lifestyle intervention (behavioral) — also listed as: group 1
• GLP-1 Receptor Agonists (drug) — also listed as: group 2
• Metformin (drug) — also listed as: group 3
• Acarbose (drug) — also listed as: group 4

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Renji Hospital Department of Endocrinology and Metabolism
  Shanghai, Shanghai Municipality, China
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Insulin (drug) — also listed as: Pre-prandial insulin, postprandial insulin

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Washington University in St Louis
  St Louis, Missouri, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Clinic for Reproductive Endocrinology, University Hospital Zurich
  Zurich, Switzerland
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• GLP-1RA (drug)
• SGLT2i (drug)
• Insulin (drug)
• Miscellany (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• INCLIVA
  Valencia, Spain
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• GLP-1 receptor agonist (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Guy's and St Thomas' NHS Foundation Trust
  London, United Kingdom
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Tirzepatide (drug) — also listed as: Tirzepatide 5、10、15mg
• Insulin Glargine (drug) — also listed as: Adjust insulin dose according to fasting plasma glucose (FBG)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Nanjing First Hospital
  Nanjing, Jiangsu, China
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Exenatide (drug) — also listed as: Bydureon, Glucagon-like peptide-1 receptor agonist

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Laboratory for Rehabilitation Neuroscience
  Gainesville, Florida, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Dulaglutide (drug) — also listed as: Trulicity
• 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl]) (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Universitätsspital Basel
  Basel, Switzerland
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Exenatide (drug)
• Placebo (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Academic Specialist Center, Center for Neurology, SLSO
  Stockholm, Sweden
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Dulaglutide (drug)
• Placebo (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• University Hospital Basel, Endocrinology, Diabetes and Metabolism
  Basel, Switzerland
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• glucagon (drug)
• Closed loop glucagon pump (device)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Joslin Diabetes Center
  Boston, Massachusetts, United States
  Site recruitment: Not reported